EP Patent

EP2439201A1 — Compounds with combined SERT, 5-HT3 and 5-HT1A activity

Assigned to H Lundbeck AS · Expires 2012-04-11 · 14y expired

What this patent protects

1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT 3 and 5-HT 1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

USPTO Abstract

1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT 3 and 5-HT 1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: EP2439201A1
Jurisdiction: EP
Classification: —
Expires: 2012-04-11
Drug substance claim: No
Drug product claim: No
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.